Company news
Neumora Therapeutics, Inc. news in 2024
Neumora Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 11, 2024
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 28, 2024
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
August 13, 2024
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 5, 2024
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
June 19, 2024
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
May 13, 2024
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 6, 2024
Neumora Therapeutics to Participate in Upcoming Conferences in May
May 5, 2024
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
April 14, 2024
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
March 12, 2024
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 6, 2024
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
January 21, 2024
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 1, 2024
Calls in 2024
Decks in 2024
- J.P. Morgan Healthcare Conference January 2024
Conference · 28 slides · Jan 8, 2024
- 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
Conference · 28 slides · January 2024